CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Ketamine +1 moredrug
Likely dose
Ketamine 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01304147
NCT01304147N/ACompleted
CompareCT.gov

Intranasal (IN) Ketamine in Treatment-Resistant Depression (TRD)

James Murrough·interventional·Posted Feb 25, 2011·Updated Feb 8, 2017

In Brief

A clinical study evaluating Ketamine and placebo for Major Depressive Disorder. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression (TRD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 25, 2011
Enrollment StartOct 1, 2011
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 15.4 years ago

Interventions

Ketaminedrug

A single dose of intranasal ketamine up to 50 mg

placebodrug

Single dose of saline intranasal